BridgeMD
New treatment option for Advanced/Metastatic Solid Tumors
Official title A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07090499
What this study is testing
What is PF-08046876?
PF-08046876 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for advanced/metastatic solid tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years of age or older
- Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
- Measurable disease
- ECOG Performance status 0-1
- Part 1: progression or relapse following standard treatments
You likely can't join if
- Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )
- Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion
- Pulmonary disease meeting protocol exclusion
- Other unacceptable abnormalities as defined by protocol
See the full eligibility criteria
- 18 years of age or older
- Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
- Measurable disease
- ECOG Performance status 0-1
- Part 1: progression or relapse following standard treatments
- Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting
- Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
- Consent to submit required pre-treatment tumor tissue as medically feasible
- Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )
- Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion
- Pulmonary disease meeting protocol exclusion
- Other unacceptable abnormalities as defined by protocol
The study team makes the final eligibility decision.
Where it's taking place
- Duarte, California, United States
- Irvine, California, United States
- Los Angeles, California, United States
- Santa Monica, California, United States
- New Haven, Connecticut, United States
- Trumbull, Connecticut, United States
- Boston, Massachusetts, United States
- Newton, Massachusetts, United States
- Nashville, Tennessee, United States
- Conroe, Texas, United States
- Houston, Texas, United States
- League City, Texas, United States
- San Antonio, Texas, United States
- Sugar Land, Texas, United States
- Toronto, Ontario, Canada
- Rio Piedras, Puerto Rico
- Barcelona, Barcelona [barcelona], Spain
- Madrid, Madrid, Comunidad de, Spain
- Madrid, Spain
- London, United Kingdom
+ 1 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Duarte, California, United States; Irvine, California, United States; Los Angeles, California, United States; Santa Monica, California, United States; New Haven, Connecticut, United States; Trumbull, Connecticut, United States and 15 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.